Systems and methods for assessing medical conditions such as inflammation, autoimmunity, and Autism Spectrum Disorder (ASD), and treatments thereof
A system for evaluating a subject, including: a processor in communication with a carbon monoxide (CO) detector, and a memory in communication with the processor having stored thereon a set of instructions which, when executed by the processor, cause the processor to: receive, from the CO detector, a measure of CO in a subject suspected of having at least one of autism spectrum disorder (ASD), autoimmunity, or inflammation; obtain a level of at least one biomarker associated with the subject based on receiving the measure of CO in the subject; and generate a report based on obtaining the level of the at least one biomarker.
1 . A system for evaluating a subject, comprising:
a housing,
a processor in communication with a carbon monoxide (CO) detector, and
a memory in communication with the processor having stored thereon a set of instructions which, when executed by the processor, cause the processor to:
receive, from the CO detector, a measure of CO in a subject suspected of having at least one of autism spectrum disorder (ASD), autoimmunity, or inflammation;
determine a measure of ASD severity associated with the subject based on receiving the measure of CO in the subject by comparing the measure of CO to a calibration curve correlating the measure of ASD severity to the measure of CO; and
report the correlation between the measure of ASD severity to the measure of CO,
wherein the CO detector, the processor, and the memory are disposed within the housing.
2 . The system of claim 1 , wherein the processor, when receiving a measure of CO in a subject, is further caused by the instructions to:
receive a level of blood carbon monoxide (SpCO) in the subject.
3 . The system of claim 1 , wherein the system further comprises a user interface,
wherein the user interface is disposed within the housing, and
wherein the housing is configured to be coupled to the subject.
4 . The system of claim 1 , wherein the measure of CO comprises an average of measurements collected at a first time point and a second time point.
5 . The system of claim 1 , wherein the processor, when generating the report, is further caused by the instructions to:
generate the report indicating a level of ganglioside-monosialic acid (GM1) in the subject.
6 . The system of claim 1 , wherein the processor, when generating the report, is further caused by the instructions to:
generate the report indicating a treatment for the subject suspected of having at least one of ASD, autoimmunity, or inflammation.
7 . The system of claim 6 , wherein the processor, when indicating the treatment for the subject suspected of having at least one of ASD, autoimmunity, or inflammation, is further caused by the instructions to:
indicate the treatment comprising administration of a probiotic to the subject suspected of having at least one of ASD, autoimmunity, or inflammation.
8 . The system of claim 7 , wherein the processor, when indicating the treatment comprising administration of a probiotic to the subject suspected of having at least one of ASD, autoimmunity, or inflammation, is further caused by the instructions to:
indicate the treatment comprising administration of Lactobacillus plantarum probiotic to the subject suspected of having at least one of ASD, autoimmunity, or inflammation.
9 . The system of claim 6 , wherein the treatment is administered to the subject suspected of having at least one of ASD, autoimmunity, or inflammation for at least 16 weeks.
10 . The system of claim 1 , wherein the processor, when generating the report, is further caused by the instructions to:
generate the report indicating a subgrouping of the subject suspected of having ASD.
11 . The system of claim 1 , wherein the processor is further caused by the instructions to:
obtain a level of at least one biomarker based on a correlation between the measure of CO and level of the at least one biomarker.
12 . A method for evaluating a subject, comprising:
providing a housing;
receiving, from a processor in communication with a carbon monoxide (CO) detector, a measure of CO in a subject suspected of having at least one of autism spectrum disorder (ASD), autoimmunity, or inflammation,
wherein the processor and the CO detector are disposed within the housing;
determining, by the processor, a measure of ASD severity associated with the subject based on receiving the measure of CO in the subject by comparing the measure of CO to a calibration curve correlating the measure of ASD severity to the measure of CO; and
reporting the correlation between the measure of ASD severity to the measure of CO.
13 . The method of claim 12 , wherein receiving the measure of CO in the subject further comprises:
receiving a level of blood carbon monoxide (SpCO) in the subject.
14 . The method of claim 12 , wherein a user interface is disposed within the housing, and
wherein the housing is configured to be coupled to the subject.
15 . The method of claim 12 , wherein the measure of CO comprises an average of measurements collected at a first time point and a second time point.
16 . The method of claim 12 , wherein generating the report further comprises:
generating the report indicating a level of ganglioside-monosialic acid (GM1) in the subject.
17 . The method of claim 12 , wherein generating the report further comprises:
generating the report indicating a treatment for the subject suspected of having at least one of ASD, autoimmunity, or inflammation.
18 . The method of claim 17 , wherein indicating the treatment for the subject suspected of having at least one of ASD, autoimmunity, or inflammation further comprises:
indicating the treatment comprising administration of a probiotic to the subject suspected of having at least one of ASD, autoimmunity, or inflammation.
19 . The method of claim 18 , wherein indicating the treatment comprising administration of the probiotic to the subject suspected of having at least one of ASD, autoimmunity, or inflammation further comprises:
indicating the treatment comprising administration of Lactobacillus plantarum probiotic to the subject suspected of having at least one of ASD, autoimmunity, or inflammation.
20 . The method of claim 17 , wherein the treatment is administered to the subject suspected of having at least one of ASD, autoimmunity, or inflammation for at least 16 weeks.
21 . The method of claim 12 , wherein generating the report further comprises:
generating the report indicating a subgrouping of the subject suspected of having ASD.
22 . The method of claim 12 , wherein the method further comprises:
obtaining a level of at least one biomarker based on a correlation between the measure of CO and the level of the at least one biomarker.